Company Overview - Black Diamond Therapeutics is developing tumor-agnostic therapies for genetically defined cancers with unmet treatment needs[6,7] - The company's MAP platform identifies oncogenic mutations across tumor types to develop spectrum-selective small molecule therapies[7] - Black Diamond is pioneering a novel scientific approach to address significant unmet medical needs in oncology[57] Pipeline and Programs - BDTX-189, an orally-available MasterKey tyrosine kinase inhibitor, is in Phase 1/2 clinical trial targeting ErbB mutations[7] - BDTX-1535, a brain-penetrant small molecule inhibitor of EGFR mutations, is advancing towards IND filing in 1H 2022[12] - BRAF and FGFR programs are in lead optimization, targeting allosteric oncogenic driver mutations with IND anticipated in 2022[12] BDTX-189 Program - BDTX-189 targets up to 30,000+ new cases across solid tumors in the US in 2020 with mutations in EGFR/HER2[21] - In NSCLC with EGFR/HER2 Exon 20 insertion mutations, BDTX-189 targets up to 7,600 cases, representing approximately 4% of ~190,000 NSCLC cases[21] - In breast cancer, BDTX-189 targets up to 8,400 cases with EGFR/HER2 Exon 20 insertions, HER2 S310 mutations, or other alloHER2 mutations, representing approximately 3% of ~280,000 breast cancer cases[21] - In solid tumors excluding breast cancer, BDTX-189 targets up to 6,000 cases with HER2 S310 mutations, representing approximately 0.5% of ~1.2 million cases[21] - In solid tumors excluding breast cancer, BDTX-189 targets up to 12,000 cases with other allo-HER2 mutations (and Solid Tumors excluding Breast Cancer and NSCLC with EGFR/HER2 Exon 20 insertion mutations), representing approximately 1% of ~1.2 million cases[21] BDTX-1535 Program - Approximately 50% of GBM tumors express oncogenic EGFR variants[38]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________ FORM 10-K ___________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _ TO _ COMMISSION FILE NUMBER 001-38501 ____________________________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _ TO _ COMMISSION FILE NUMBER 001-38501 ___________________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _ TO _ COMMISSION FILE NUMBER 001-38501 ________________________ ...

BLACK DIAMOND THERAPEUTICS Precision Oncology Medicines Pioneering the Development of Small Molecule, Tumor-Agnostic Therapies June │ 2020 1 Important Notice and Disclaimers This presentation contains "forward-looking statements" of Black Diamond Therapeutics, Inc. ("Black Diamond," "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding our ability to advance and expa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _ TO _ COMMISSION FILE NUMBER 001-38501 _______________________ ...

Table of Contents ___________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________ FORM 10-K ___________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _ TO _ COMMISSION FILE N ...